FDA Clears Osmetech's Warfarin Sensitivity Test | GenomeWeb
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Osmetech’s eSensor Warfarin Sensitivity Test, the London-based firm announced today.
 
The genetic test is used to aid physicians in identifying patients who are at risk for increased sensitivity to the blood-thinning drug warfarin. Osmetech submitted its application with the FDA for the test at the beginning of this year.
 
The firm said that the FDA also cleared its second-generation eSensor XT-8 molecular diagnostics platform.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.